BiondVax Pharmaceuticals Ltd. (BVXV): Price and Financial Metrics


BiondVax Pharmaceuticals Ltd. (BVXV): $1.19

-0.03 (-2.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BVXV Stock Price Chart Interactive Chart >

Price chart for BVXV

BVXV Price/Volume Stats

Current price $1.19 52-week high $4.19
Prev. close $1.22 52-week low $1.00
Day low $1.16 Volume 27,000
Day high $1.22 Avg. volume 742,563
50-day MA $1.31 Dividend yield N/A
200-day MA $1.68 Market Cap 13.51M

BiondVax Pharmaceuticals Ltd. (BVXV) Company Bio


Biondvax Pharmaceuticals Limited is a pharmaceutical company that develops intra-nasal flu vaccines.


BVXV Latest News Stream


Event/Time News Detail
Loading, please wait...

BVXV Latest Social Stream


Loading social stream, please wait...

View Full BVXV Social Stream

Latest BVXV News From Around the Web

Below are the latest news stories about BiondVax Pharmaceuticals Ltd that investors may wish to consider to help them evaluate BVXV as an investment opportunity.

BiondVax to Present at Aegis Virtual Conference

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 23rd at 9:30am ET.

Yahoo | February 22, 2022

BiondVax to Present at BIO CEO & Investor Conference

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that CEO Amir Reichman is presenting at the BIO CEO & Investor Conference being held this week.

Yahoo | February 15, 2022

BVXV: Building a Pipeline of VHH Antibody Drug Candidates…

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Beginning the Transition to a Fully Integrated Biopharmaceutical Company BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical company that is developing treatments for infectious diseases and other illnesses. Recently, BiondVax signed definitive agreements with the Max Plank Institute for Biophysical

Yahoo | February 10, 2022

BiondVax to Present at Edison Group's Open House Conference

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it is presenting at the Edison Open House: Global Healthcare 2022 conference.

Yahoo | January 26, 2022

BiondVax to Present at H.C. Wainwright Bioconnect Virtual Conference

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present a company overview at the H.C. Wainwright Bioconnect Virtual Conference.

Yahoo | January 10, 2022

Read More 'BVXV' Stories Here

BVXV Price Returns

1-mo N/A
3-mo -28.31%
6-mo -49.36%
1-year -59.25%
3-year -79.34%
5-year -86.45%
YTD -49.36%
2021 -16.37%
2020 -69.75%
2019 94.76%
2018 -11.01%
2017 60.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4686 seconds.